Vioxx-Like Drug Gets Mixed Reviews
14th Nov 2006, 00:34 GMT
The 1st published studies of Arcoxia, the drug that Merck &.
Vioxx-Like Drug Gets Mixed Reviews related news:
- Vioxx-Like Drug Gets Mixed Reviews — Dayton Daily News National Headlines
- Mixed reviews for Vioxx successor — MSNBC.com: Health
- Merck's Arcoxia Draws Mixed Reviews — WSJ.com: US Business
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Tests of new Merck painkiller criticized — baltimoresun.com - health & science
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
Latest news from StratWire - Business of Healthcare NewsFeed:
- Alliance Names New COO
- NHCAA to Award Those Who Fight and Expose the Deadly Side of Health Care Fraud
- More Than 2 mln Cancer Patients Treated with BrainLAB m3 Shaped Beam Radiosurgery
- PA's Continuing Trend Towards Total Body Reconstruction Keeps Consumers Demanding Comprehensive Direct-To-Consumer-Education (DTCE )
- Dr Farzad Yaghouti of Global Laser Vision San Diego Wins 'Best Lasik Surgeon 2006'
- 1st Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Medical Mutual of OH Financial Investigator Wins Top Nat'l Fraud-Fighting Award
- Intelligent Medical Objects and Bond Technologies Sign Multi-year Agreement
- M-CARE's Medicaid Plan Recognized as One of the Top Health Plans by US News & World Report/NCQA
- Fitch: MCH rates 'A-' on bonds